Background and Purpose-We demonstrated previously that treatment with selective -opioid receptor (KOR) agonist BRL 52537 hydrochloride [(Ϯ)-1-(3,4-dichlorophenyl) acetyl-2-(1-pyrrolidinyl) methylpiperidine] (1) has a long therapeutic window for providing ischemic neuroprotection, and (2) attenuates ischemia-evoked NO production in vivo in rats. Neuronally derived NO has been shown to be deleterious in the male but not in the female rodent model of focal ischemic stroke. We tested the hypothesis that BRL provides significant neuroprotection from transient focal ischemia in male but not in female rats. Methods-Halothane-anesthetized adult male and female Wistar rats (250 to 275 g) were subjected to 2 hours of middle cerebral artery occlusion (MCAO) by the intraluminal suture technique. Adequacy of MCAO and reperfusion was monitored with laser-Doppler flowmetry over the ipsilateral parietal cortex. In the first experiment, male and female rats were treated in a blinded randomized fashion with vehicle saline or 1 mg/kg per hour BRL infusion started at the onset of reperfusion and continued for 22 hours. In the second experiment, ovariectomized (OVX) female rats were treated with vehicle or BRL. Infarct volume in the cortex and caudoputamen (CP) complex was assessed by triphenyl tetrazolium chloride staining at 72 hours after MCAO. Results-Infarct volume (percentage of ipsilateral structure; meanϮSEM) was attenuated significantly in male rats with BRL treatment (cortex 23Ϯ5%; CP 44Ϯ6%; nϭ15) compared with vehicle-treated male rats (cortex 38Ϯ4%; CP 66Ϯ4%; nϭ15) but not in female rats (BRLϪcortex 26Ϯ6; CP 55Ϯ8%; vehicleϪcortex 26Ϯ5; CP 62Ϯ5%; nϭ10 each). Neurologic deficit score was improved in BRL-treated male rats but not in female rats. Infarct volume was not different in OVX female rats treated with vehicle or BRL. Conclusions-These data: (1) demonstrate that this dose of selective KOR agonist provides ischemic neuroprotection in male but not female rats, (2) demonstrate that the lack of protection by BRL is not attributable to circulating ovarian hormones, and (3) highlight the importance of using animal models of both sexes in preclinical studies of experimental ischemia.
K appa ()-opioid receptors (KORs) have been shown to play an important role in modulating ischemic brain injury. Several studies have demonstrated KOR agonists to attenuate histological brain injury [1] [2] [3] as well as improve functional recovery in animal models of global as well as focal cerebral ischemia. 4 -7 We have shown previously that the selective KOR agonist has a long therapeutic window for providing ischemic neuroprotection after transient focal ischemia in the rat model of middle cerebral artery occlusion (MCAO), 8 and this neuroprotective action is dose dependent 6 and receptor selective. 7 There is abundance of literature demonstrating the effects of KOR agonists on a variety of neurotransmitter systems. 9 -11 Although some in vivo studies demonstrated that KOR agonists modulate dopaminergic neurotransmission in the substantia nigra, neostriatum, and the mesolimbic system, 9 -11 we did not observe modulation of ischemia-evoked acute release of dopamine or its metabolites. 8 We have demonstrated previously that BRL 52537 attenuates ischemia-evoked NO production in the striatum in vivo and have postulated that this may account for its neuroprotective action, 6 although the precise signaling of this interaction remains unclear.
It is well known from epidemiologic studies that gender plays a major role in the incidence and prevalence of ischemic stroke. 12 In addition, mounting evidence suggests genderspecific responses to brain injury after experimental ische-mia. [13] [14] [15] [16] Animal studies indicate that endogenous sex steroids influence outcome after ischemic stroke. Estrogen has been widely shown to protect brain after ischemic stroke, and these observations have been consistent across animal models and genetic strains. [13] [14] [15] [16] In addition to endogenous neuroprotection from estrogen, emerging data suggest that excitotoxic pathways may have a differential effect in males versus females. For example, neuronally derived NO has been shown to be deleterious in the male but not in the female rodent model of focal ischemic stroke. 17 Previous preclinical studies on ischemic neuroprotection have paid little or no attention to these innate gender-specific differences in stroke outcome.
In this study, we tested the hypothesis that the highly selective KOR agonist BRL 52537 hydrochloride [(Ϯ)-1-(3,4-dichlorophenyl) acetyl-2-(1-pyrrolidinyl) methylpiperidine)] 18,19 acts in a sex-specific manner to provide ischemic neuroprotection in a well-characterized model of transient focal ischemia. We further tested the hypothesis that BRL attenuates ischemic experimental stroke in the female in the absence of neuroprotection conferred by circulating female sex steroids.
Materials and Methods

MCAO Model
All experimental protocols were approved by the institutional animal care and use committee and conformed to the National Institutes of Health guidelines for the care and use of animals in research. All techniques are as described previously. 6 -8,13,14 In brief, adult Wistar rats (250 to 275 g) were anesthetized with halothane (1.0% to 2.0%) in air and allowed to ventilate spontaneously. Concentration of inspired oxygen was adjusted between 25% and 30% to maintain PaO 2 between 100 and 150 mm Hg. With aseptic surgical techniques, the right femoral artery was cannulated to monitor arterial blood pressure and arterial blood gases. The femoral vein was cannulated, tunneled subcutaneously, and exteriorized for vascular access and drug administration. 6 -8 Rectal temperature was maintained throughout surgical procedures, during ischemia, and until emergence from anesthesia. Transient focal ischemia (2 hours) was produced by MCAO using an intraluminal suture technique in combination with laser-Doppler flowmetry (LDF; Moor Instruments Ltd.; Model MBF3D) as described previously 20 with modifications. 6 -8,13,14 
Experimental Groups
All experiments were performed in a blinded, randomized fashion. In the first series of experiments (nϭ62), male and female rats were treated with continuous intravenous infusion of vehicle (saline) or 1 mg/kg per hour BRL 52537 (Tocris) at onset of reperfusion and continued for 22 hours. All infusions were at a rate of 0.3 mL per hour.
In a second series of experiments (nϭ19), ovariectomy was performed as described previously 13 in female rats at the age of 10 to 12 weeks. Briefly, under halothane anesthesia (1% to 2% via snout mask in O 2 -enriched air), the ovary was accessed through a lateral abdominal incision, and the ovarian artery and vein were clamped with a fine surgical hemostat and ligated. The ovary was then resected, surgical wounds closed, and the animal allowed recovery for 1 week. Rats were then randomized to treatment with continuous intravenous infusion of vehicle or 1 mg/kg per hour BRL 52537 at onset of reperfusion and continued for 22 hours. Plasma estrogen levels were determined before MCAO and at the completion of the experimental protocol by radioimmunoassay, as described previously. 13, 14 In both series of experiments, rats were allowed to emerge from anesthesia at 30 minutes of reperfusion. After treatments for 22 hours, the femoral venous catheter was removed and the vein was ligated. Rats were housed in separate cages at room temperature (22°C to 24°C) during emergence from anesthesia and thereafter until they were euthanized. Neurologic examination 7, 8, 21, 22 was performed daily to assess a neurologic deficit score (NDS) comprising consciousness (0, normal; 1, restless; 2, lethargic; and 3, stuporous), gait (0, normal; 1, paw adduction; 2, unbalanced walking; 3, circling; 4, unable to stand; 5, no movement), limb tone (0, normal; 1, spastic, 2, flaccid), and pain reflex (0, normal; 2, hypoactive; 4, absent). On day 4 of reperfusion (72 hours after MCAO), rats were deeply anesthetized with 5% halothane and decapitated. Each brain was harvested and sliced into 7 2-mm-thick coronal sections for staining with 1% triphenyltetrazolium chloride, as described previously. 6 -8,13,14 Infarct volume was measured with digital imaging. The infarcted area was numerically integrated across each section and over the entire ipsilateral hemisphere. Infarct volumes were measured separately in cerebral cortex and caudoputamen (CP) complex and expressed as a percentage of the ipsilateral structure volume as described previously. 13, 14 
Statistical Analysis
One-way ANOVA was performed to examine the differences of mean LDF measurements across various time points and physiological variables at preischemia, ischemia, and reperfusion among 4 experimental groups (ie, male-saline, male-BRL, female-saline, and female-BRL). Newman-Keuls post hoc comparisons were further performed to test between-group differences. Effect of treatment on infarct volume was tested by 1-way ANOVA separately for each gender because treatment effect was of primary interest. Data are presented as meanϮSEM. NDS is presented as median (with 25% and 75% quartiles) and analyzed by the nonparametric MannWhitney U test.
Results
In the first series of experiments, mortality rate before completion of the experimental protocol (72 hours after MCAO) was as follows: 1 of 16 in male-saline controls secondary to subarachnoid hemorrhage (SAH), 1 of 17 in male-BRL group with SAH, 2 of 12 in female-saline controls (with SAH), and 3 of 17 in female-BRL group (2 with focal hemorrhages in the infarct). One rat in the male-BRL, and 4 in female-BRL groups did not achieve a reduction in LDF signal to Ͻ40% and were not included in the analysis. Thus, the final number of rats that successfully completed the experimental protocol and were included in the final analysis were: male-saline controls, nϭ15; male-BRL, nϭ15; femalesaline controls, nϭ10; and female-BRL, nϭ10.
Mean arterial blood pressure, partial pressure of arterial carbon dioxide (PaCO 2 ) and oxygen (PaO 2 ), pH, temporalis, and rectal temperature were within normal physiological ranges in all animals at baseline and during MCAO and early reperfusion (Table 1) . LDF-determined cerebral perfusion was not different in various treatment groups during MCAO (male-saline, 26Ϯ3%; male-BRL, 29Ϯ4%; female-saline, 28Ϯ3%; and female-BRL, 30Ϯ4%). Similarly, LDF was promptly restored on withdrawal of intraluminal suture during reperfusion in all treatment groups.
On days 3 and 4 of recovery, the median NDS in the male-BRL was significantly better than the male-saline control group (Table 2) . Infarct volume (percentage of ipsilateral structure) was significantly attenuated in male rats with BRL treatment (cortex 23Ϯ5%; CP 44Ϯ6%; nϭ15) compared with vehicle-treated male rats (cortex 38Ϯ4%; CP 66Ϯ4%; nϭ15; Figure 1 ). However, in female rats, BRL treatment did not significantly reduce infarct volume compared with female controls (saline controls: cortex 26Ϯ6%; CP 55Ϯ8%; BRL: cortex 26Ϯ5%; CP 62Ϯ5%; nϭ10 each; Figure 2 ).
In the second series of experiments, there were no differences in physiological variables between the 2 experimental groups at baseline or during MCAO and early reperfusion (data not shown). Similarly, LDF-determined, intraischemic cerebral perfusion was not different in ovariectomized (OVX) female rats with postischemic vehicle (35Ϯ1%) and BRL (36Ϯ1%) treatment. Three BRL-treated and 2 vehicle-treated rats died before completion of the experimental protocol. Two rats were excluded because ovariectomy did not result in a reduction in plasma estrogen levels. Estrogen levels in rats that successfully completed the protocol (nϭ6 per group) were similar before MCAO (OVX-vehicle 4.8Ϯ1.6 pg/mL; OVX-BRL 4.4Ϯ2.2 pg/mL) and at the end of the experiment (OVX-vehicle 4.3Ϯ2.1 pg/mL; OVX-BRL 2.2Ϯ2.8 pg/mL) in the 2 treatment groups. There were no differences in daily NDS (data not shown), and infarct volume (72 hours after MCAO) was similar in the 2 experimental groups in the cortex (OVX-vehicle 20Ϯ7%; OVX-BRL 19Ϯ7%) and CP complex (OVX-vehicle 54Ϯ3%; OVX-BRL 60Ϯ6%; Figure 3 ).
Discussion
This study demonstrates 2 important findings. First, intravenous administration of selective KOR agonist BRL 52537 confers ischemic neuroprotection that is specific to the male animal. Second, lack of ischemic neuroprotection seen in 
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female rats is not attributable to an interaction between the KOR agonist and female sex steroids. One mechanism by which BRL reduces ischemic damage in male animals is through reduction of early NO toxicity. However, we have shown recently that ablation of neuronal NO synthase (nNOS) activity does not alter ischemic outcome in female brain. Our data support that the sex-specific efficacy of BRL is related to its potential to reduce NO toxicity and speculate that the compound would be best used as an anti-ischemic therapy for the male.
Ischemic Neuroprotection With BRL 52537
KOR agonists have been of interest as potential therapy for ischemic neuroprotection for several years. As in our previous studies, 6 -8 we used BRL 52537 hydrochloride, 18,19 a water-soluble agent that is highly specific for the KOR (eg, Ki 0.24 nmol/L; Ki 1560 nmol/L). We have shown that BRL 52537 provides significant ischemic neuroprotection when the onset of treatment is delayed for up to 6 hours of reperfusion after 2 hours of MCAO in the rat. 8 This observed neuroprotection with BRL is without alteration in core body temperature 7 and without any significant effects on physiological parameters evaluated within our study. Furthermore, prolonged treatment (4 days) does not result in gross neuropathology or myelin injury in naive nonischemic rats. 6 Data from several previous studies support that antiexcitotoxic mechanisms may be important in the neuroprotection provided by KOR agonists in cerebral ischemia. In vitro studies have demonstrated that KOR agonists modulate glutamate toxicity via inhibition of presynaptic glutamate release, possibly by closing N-type Ca 2ϩ channels and inhibiting excitatory postsynaptic potentials by attenuating presynaptic Ca 2ϩ influx. 6 Others have demonstrated attenuation of glutamate release 1 with graded ischemia in experimental stroke with a KOR agonist, as well as modulation of the inhibitory neurotransmitter ␥-aminobutyric acid. 23 In contrast to previous in vitro studies, neuroprotective doses of BRL did not alter the acute release of dopamine or its metabolites in the ischemic striatum in vivo in our study. 8 In keeping with previous in vitro studies, we demonstrated that neuroprotective doses of BRL attenuate ischemia-evoked striatal NO production and have postulated that the consequent reduction in early NO toxicity may represent a mechanism for the neuroprotective action in ischemic stroke of this KOR agonist. 6
Gender-Selective Ischemic Neuroprotection With BRL 52537
Epidemiologic studies have highlighted that there are gender differences in the incidence and prevalence of human ischemic stroke. 12 Mounting evidence from laboratory-based studies indicate gender-specific responses to many forms of brain injury, [13] [14] [15] [16] and endogenous sex steroids have been implicated in this differential outcome after experimental ischemic stroke. Although the role of exogenous estrogens in stroke prevention is unproven, the ability of the steroid to reduce stroke sensitivity (ie, damage once an ischemic insult has occurred) has been widely and uniformly demonstrated. [12] [13] [14] [15] [16] [17] Progesterone is also a neuroprotectant in ischemic injury. 24 It is conceivable that the neuroprotective actions of BRL are obscured in the female because they already have smaller infarct volumes compared with male rats. However, the present study shows that BRL protects only the male brain and performs no better in females with or without native ovarian sex steroids. Therefore, the sex specificity of BRL cannot be attributed to the ability of protective estradiol or progesterone to obscure its actions. This lack of effect in OVX females is consistent with an emerging concept that excitotoxic-signaling pathways may differ in females, independently of hormone status. Brain stem pain modulating circuitry has been shown to be sexually dimorphic with respect to KOR receptor function, although this has not been correlated with hormonal status. 25 Cultured neurons from males and females are differentially susceptible to nitrosative stress and excitotoxicity and respond to therapies that are sexually dimorphic. 26 Neuronally derived NO has been shown to be deleterious in the male but not in the female rodent model of focal ischemic stroke. 17 Although male mice lacking nNOS are significantly protected from brain injury after focal ischemia, female mice deficient in nNOS do not have any reduction in infarct volume compared with their wild-type counterparts. 17, 26 Further studies indicate that loss of nNOS by genetic knockout or pharmacological inhibition can actually increase ischemic damage in the female rodent 27 and that loss of poly(ADP-ribose) polymerase-1 activation does not protect female rodents. 27, 28 In conclusion, these data demonstrate that a continuous intravenous infusion of the potent and selective KOR agonist BRL 52537 attenuates stroke damage in male but not female rats subjected to transient focal ischemia. The precise mechanism by which protection is sex specific is not yet elucidated, but the lack of protection in females is not dependent on presence or absence of female sex steroids. Preclinical studies of ischemic neuroprotection have not been stratified by sex in examining experimental stroke outcome. Our study highlights the importance of using animal models of both sexes in experimental studies of ischemic neuroprotection. Furthermore, there is a potential that some therapeutic agents could be effective in one sex only, a characteristic that would be most important in designing optimum clinical trials for these new drugs.
